Neovasc and GADA Sponsor Session at the 40th Annual (GISE) National Congress of the Italian Society of Interventional Cardiology


Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, and GADA Spa today announced their co-sponsoring of a major educational session at the prestigious GISE Congress, which will be held at the MICO Congress Center in Milan, Italy from October 15-18, 2019.

The symposium, titled “A Proven Evidence-Based Therapy When Angina Persists,” is scheduled for October 16th and will feature an internationally recognized scientific faculty. Moderated by Sergio Berti, M.D., and Francesco Giannini, M.D., the session will also include a presentation from Professor Shmuel Banai, M.D., Neovasc’s Medical Director.

During the symposium, results of the Italian Reducer Registry will be presented. The registry has enrolled over 180 patients and is one of the largest studies to date. Additionally, the results of a specialized third-party survey targeting cardiologists and reviewing the clinical path of patients with refractory angina will be discussed.

Fred Colen, President & CEO, Neovasc

“As leaders in the treatment of refractory angina, we are pleased to have the opportunity to support an important educational session at one of the most prestigious European Congresses dedicated to the betterment of Cardiology practices and treatments,” said Fred Colen, President and Chief Executive Officer of Neovasc. “The panel will be a shared clinical experience of key opinion leaders, providing insights into the treatment options for the growing problem and impact on patients of refractory angina. This session is an opportunity to gain a better understanding of the Reducer rationale, and a presentation of the significant clinical evidence of the effectiveness and safety of the Reducer therapy for refractory angina.”

The Neovasc Reducer™, which is CE Marked and available in the European Union, is expected to continue to have a significant role in treating a large and increasing population of patients suffering from refractory angina due to various degrees of coronary artery disease, who have limited options.

Antonio Biagio De Marinis , CEO, GADA

Biagio De Marinis, GADA CEO, underlines how the partnership between Neovasc and Gada represents an important element in the Gada group’s growth plan: “Together we work to support Italian cardiologists and provide an important opportunity for patients suffering from chronic refractory angina. We are proud to organize this symposium together with the Italian Society of Interventional Cardiology (GISE) for the benefit of patients suffering from refractory angina.”

Cardiology Magazine